| Literature DB >> 25013467 |
Bin Wang1, You-Ming Ding1, Ping Fan1, Bing Wang1, Jun-Hui Xu1, Wei-Xing Wang1.
Abstract
Hepatocellular carcinoma (HCC) is a serious threat to human health. HCC is a malignant tumor and its invasion and metastasis are the result of multigene interactions. Matrix metalloproteinase-2 (MMP-2) is capable of degrading the majority of components of the extracellular matrix and is regarded to closely correlate with tumor invasion and metastasis. Furthermore, the hypoxia-inducible factor 1α (HIF-1α) is an important transcription factor, which is closely associated with the process of tumor growth. The aim of the present study was to investigate the expression of MMP2 and HIF-1α) in HCC, and the relationship between MMP2/HIF-1α protein expression and the clinical/pathological characteristics of HCC. The mRNA levels of MMP2 and HIF-1α were detected in 32 cases of HCC and the corresponding normal adjacent tissues with fluorescence-based quantitative polymerase chain reaction (qPCR). The protein expression of MMP2 and HIF-1α was assessed in 45 HCC cases and 33 cases of corresponding normal adjacent tissue, using immunohistochemical methods. The association between MMP2/HIF-1α and pathological features of HCC, and the correlation between MMP2 and HIF-1α were analyzed. The Kaplan-Meier method was used to assess the impact of MMP2 and HIF-1α expression on survival. The fluorescence-based qPCR demonstrated that MMP2 and HIF-1α mRNA expression levels in the HCC tissues were 0.84±0.17 and 0.87±0.11, respectively, which were significantly higher than those in the adjacent normal tissues (0.70±0.13 and 0.68±0.13, respectively; P<0.05). Immunohistochemical analysis revealed that MMP2 and HIF-1α protein expression in the HCC tissues was 63.1 and 70.8%, respectively, which was also higher than that in the adjacent normal tissues (34.2 and 36.8%, respectively). There was no significant correlation between the expression of MMP2 or HIF-1α protein and the age or gender of patients with HCC (P>0.05). However, there was significant correlation between MMP2 or HIF-1α protein expression and tumor size, metastasis, presence of a capsule and clinical TNM staging of HCC. Their expression also had a significant effect on patient survival time. In conclusion, MMP2 and HIF-1α are overexpressed in HCC, and the MMP2 signaling pathway may promote the development of HCC together with HIF-1α.Entities:
Keywords: gene expression; hepatocellular carcinoma; hypoxia-inducible factor 1α; matrix metalloproteinase 2
Year: 2014 PMID: 25013467 PMCID: PMC4081179 DOI: 10.3892/ol.2014.2189
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
The expression levels of MMP2 and HIF-1α mRNA in HCC and paracancerous tissues (2−ΔΔCt).
| Group | n | MMP2 | HIF-1α |
|---|---|---|---|
| HCC | 33 | 0.80±0.19 | 0.91±0.11 |
| Paracancerous | 33 | 0.68±0.15 | 0.65±0.19 |
| P-value | 0.001 | <0.001 |
Expression data are presented as the mean ± SD. MMP2, matrix metalloproteinase 2; HIF-1α, hypoxia-inducible factor 1α; HCC, hepatocellular carcinoma.
Figure 1Expression levels of MMP2 and HIF-1α mRNA in HCC and paracancerous tissues. MMP2, matrix metalloproteinase 2; HIF-1α, hypoxia-inducible factor 1α; HCC, hepatocellular carcinoma.
Figure 2Expression of MMP2 and HIF-1α in HCC and paracancerous tissues, by immunohistochemistry. (A) Negative MMP2 expression in paracancerous tissues. (B) Positive MMP2 expression in HCC tissues. (C) Negative HIF-1α expression in paracancerous tissues. (D) Positive HIF-1α expression in HCC tissues. MMP2, matrix metalloproteinase 2; HIF-1α, hypoxia-inducible factor 1α; HCC, hepatocellular carcinoma. Magnification, ×200.
The expression of MMP2 and HIF-1α protein in HCC and paracancerous tissues.
| Expression, n (%) | |||
|---|---|---|---|
|
| |||
| Group | n | MMP2-positive | HIF-1α-positive |
| HCC | 45 | 28 (62.22) | 32 (71.11) |
| Paracancerous | 33 | 8 (24.24) | 10 (30.30) |
| P-value | 0.003 | 0.001 | |
MMP2, matrix metalloproteinase 2; HIF-1α, hypoxia-inducible factor 1α; HCC, hepatocellular carcinoma.
Correlation between MMP2 and HIF-1α mRNA expression and clinicopathological features.
| Clinicopathological features | MMP2 mRNA | P-value | HIF-1α mRNA | P-value |
|---|---|---|---|---|
| Age, years | 0.679 | 0.685 | ||
| ≤59 | 0.86±0.18 | 0.90±0.13 | ||
| ≥60 | 0.83±0.16 | 0.84±0.08 | ||
| Gender | 0.566 | 0.744 | ||
| Male | 0.90±0.16 | 0.88±0.11 | ||
| Female | 0.80±0.17 | 0.86±0.12 | ||
| AFP level, ng/l | 0.234 | 0.197 | ||
| >400 | 0.84±0.18 | 0.89±0.13 | ||
| ≤400 | 0.75±0.16 | 0.74±0.08 | ||
| Histological grade | 0.418 | 0.279 | ||
| High differentiation | 0.80±0.15 | 0.88±0.11 | ||
| Middle differentiation | 0.83±0.20 | 0.89±0.12 | ||
| Low differentiation | 0.91±0.13 | 0.82±0.08 | ||
| Tumor diameter, cm | 0.033 | 0.030 | ||
| ≤5cm | 0.75±0.21 | 0.82±0.08 | ||
| >5cm | 0.91±0.16 | 0.91±0.12 | ||
| Metastasis | 0.021 | 0.049 | ||
| Positive | 0.90±0.13 | 0.90±0.12 | ||
| Negative | 0.76±0.18 | 0.82±0.08 | ||
| Capsule | 0.012 | 0.018 | ||
| Positive | 0.75±0.12 | 0.81±0.12 | ||
| Negative | 0.91±0.19 | 0.90±0.07 | ||
| TNM stage | 0.006 | 0.016 | ||
| I and II | 0.75±0.19 | 0.81±0.07 | ||
| III and IV | 0.91±0.06 | 0.91±0.03 |
Data are presented as the mean ± SD. MMP2, matrix metalloproteinase 2; HIF-1α, hypoxia-inducible factor 1α.
Correlation with MMP2 and HIF-1α protein expression and clinicopathological features.
| MMP2 protein, n | HIF-1α protein, n | |||||
|---|---|---|---|---|---|---|
|
|
| |||||
| Clinicopathological features | Positive | Negative | P-value | Positive | Negative | P-value |
| Age, years | 0.751 | 0.655 | ||||
| ≤59 | 15 | 9 | 18 | 9 | ||
| ≥60 | 13 | 8 | 14 | 4 | ||
| Gender | 0.516 | 0.512 | ||||
| Male | 18 | 10 | 20 | 6 | ||
| Female | 10 | 7 | 12 | 7 | ||
| AFP level, ng/l | 0.121 | 0.012 | ||||
| >400 | 20 | 13 | 20 | 7 | ||
| ≤400 | 8 | 4 | 12 | 6 | ||
| Histological grade | 0.325 | 0.224 | ||||
| High | 9 | 3 | 10 | 2 | ||
| Intermediate | 9 | 4 | 15 | 5 | ||
| Low | 10 | 3 | 7 | 6 | ||
| Tumor diameter, cm | 0.024 | 0.039 | ||||
| ≤5 | 6 | 9 | 10 | 3 | ||
| >5 | 22 | 8 | 22 | 10 | ||
| Metastasis | 0.012 | 0.038 | ||||
| Positive | 19 | 8 | 22 | 7 | ||
| Negative | 9 | 9 | 10 | 6 | ||
| Capsule | 0.023 | 0.033 | ||||
| Positive | 15 | 4 | 13 | 8 | ||
| Negative | 13 | 13 | 19 | 5 | ||
| TNM stage | 0.028 | 0.024 | ||||
| I and II | 9 | 9 | 10 | 9 | ||
| III and IV | 19 | 8 | 22 | 4 | ||
MMP2, matrix metalloproteinase 2; HIF-1α, hypoxia-inducible factor 1α.
Figure 3Spearman’s correlation analysis of MMP-2 and HIF-1 mRNA expression in hepatocellular carcinoma tissues. MMP2, matrix metalloproteinase 2; HIF-1α, hypoxia-inducible factor 1α.
Correlation between MMP2 and HIF-1α.
| MMP2 protein | ||||
|---|---|---|---|---|
|
| ||||
| HIF-1α protein | Negative (n=11) | Positive (n=28) | rs value | P-value |
| Negative | 9 | 4 | 0.521 | <0.001 |
| Positive | 8 | 24 | ||
MMP2, matrix metalloproteinase 2; HIF-1α, hypoxia-inducible factor 1α.
Correlation between MMP2 and HIF-1α expression and survival data for patients with HCC.
| Survival time, months | ||||
|---|---|---|---|---|
|
| ||||
| Target protein | Expression | Mean | 95% CI | P-value |
| MMP2 | Positive | 15.4 | 10.9–20.1 | 0.040 |
| Negative | 23.4 | 17.3–30.5 | ||
| HIF-1α | Positive | 14.8 | 12.1–19.4 | 0.009 |
| Negative | 22.6 | 17.2–27.5 | ||
| MMP2+ | HIF-1α+ | 11.5 | 9.2–14.3 | 0.226 |
| HIF-1α− | 17.3 | 12.3–22.4 | ||
| MMP2− | HIF-1α+ | 18.9 | 14.3–22.3 | 0.017 |
| HIF-1α− | 23.8 | 17.9–30.6 | ||
MMP2, matrix metalloproteinase 2; HIF-1α, Hypoxia-inducible factor 1α; HCC, hepatocellular carcinoma.